0
0
Home > Pharmaceuticals >  Gastrointestinal >  Non-Alcoholic Fatty Liver Disease (NAFLD) Disease – Global Clinical Trials Review, H1 2020

Non-Alcoholic Fatty Liver Disease (NAFLD) Disease – Global Clinical Trials Review, H1 2020

GlobalData's clinical trial report, “Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2020" provides an overview of Non Alcoholic Fatty Liver Disease (NAFLD) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non Alcoholic Fatty Liver Disease (NAFLD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

Pfizer Inc

AstraZeneca Plc

Galmed International Ltd

Gilead Sciences Inc

Novartis AG

Allergan Plc

GlaxoSmithKline Plc

NeuroBo Pharmaceuticals Inc

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials 28

Prominent Drugs 29

Clinical Trial Profile Snapshots 30

Appendix 456

Abbreviations 456

Definitions 456

Research Methodology 457

Secondary Research 457

About GlobalData 458

Contact Us 458

Source 459

List of Tables

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region, 2020* 7

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020* 8

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020* 9

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020* 10

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2020* 11

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries, 2020* 12

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2020* 13

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2020* 14

Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2020* 15

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020* 16

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020* 17

Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2020* 18

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020* 19

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020* 20

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase, 2020* 21

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2020* 22

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2020* 23

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2020* 24

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019 25

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020* 26

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2020* 27

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* 28

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020* 29

List of Figures

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region (%), 2020* 7

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020* 8

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020* 9

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020* 10

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020* 11

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries (%), 2020* 12

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2020* 13

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2020* 14

Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2020* 15

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020* 16

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020* 17

Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2020* 18

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020* 19

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020* 20

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase (%), 2020* 21

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2020* 22

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2020* 23

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2020* 24

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019 25

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020* 26

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2020* 27

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* 28

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020* 29

GlobalData Methodology 457

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports